A clinical cohort study of CREB3L1 in a thyroid cancer risk stratification strategy

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200064199

Enrollment

Unknown

Registered

2022-09-30

Start date

2022-10-10

Completion date

Unknown

Last updated

2023-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

thyroid cancer

Interventions

Gold Standard:2017 4th WHO classification of thyroid tumors

Index test:Comparison of positive expression localization, positive rate, antibody concentration dilution ratio between HX-CREB3L1 monoclonal antibody and control antibody (sc-514635) in the standard

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. PTC, PDTC, and ATC pathology were collected according to the 2017 WHO thyroid cancer pathological staging, the pathological tissue samples, including puncture specimens and surgical specimens; 2. Surgical resection or gross needle aspiration specimens; 3. Specimens from patients without neoadjuvant therapy (radiotherapy, chemotherapy, targeted therapy, and immunotherapy) before surgery or by coarse needle aspiration; 4. Two pathologists to determine the type of pathology.

Exclusion criteria

Exclusion criteria: Containing 2 or more tumor components.

Design outcomes

Primary

Measure	Time frame
positive rate;	—

Countries

China

Contacts

Public ContactLuo Han

West China Hospital, Sichuan University

luohan-hx@scu.edu.cn+86 18080605139

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026